All In Biotech

Free tool

FAERS Monitor: Rybrevant

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761210 or its brand name (Rybrevant, Amivantamab-Vmjw). Reports on generic versions are filed under their own applications.

Reports

3,576

Serious

2,464

69% of reports

Hospitalization

748

Death reported

273

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • infusion related reaction756
  • rash507
  • off label use267
  • paronychia178
  • dyspnoea128
  • non-small cell lung cancer118
  • nausea117
  • skin toxicity89
  • oxygen saturation decreased88
  • stomatitis87
  • fatigue84
  • hypotension84
  • death80
  • diarrhoea80
  • flushing80

Reports by year received

View as table
YearReports
202166
2022154
2023203
2024592
20251,482
20261,079

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,583 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
paronychiaSignal178248.2214.441,830
non-small cell lung cancerSignal118148.5124.116,725
skin toxicitySignal8994.176.57,979
infusion related reactionSignal75667.863.749,310
oxygen saturation decreasedSignal889.27.5638
stomatitisSignal878.46.9565
rashSignal5076.86.32,577
flushingSignal804.63.7225
hypotensionSignal842.52.072
off label use2671.81.697
dyspnoea1281.31.110
nausea1170.90.72
diarrhoea800.70.68
fatigue840.60.518
death800.50.431

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.